Charcot Marie Tooth Disease - CMT Disease - Hereditary Neuropathy

Too often, important scientific discoveries never enter the pharmaceutical research phase due to lack of guidance, interest, or incentive.  At HNF, we are not only committed to funding cutting-edge basic science research, we are also committed to seeing that our research is continued by pharmaceutical companies with the goal of producing a drug that can cure or treat CMT. In order to ensure that our research is continued on the pharmaceutical level, HNF is already working with pharmaceutical consultants to ensure that our research is being completed to industry standard.   We have also structured our strategy to ensure that there is sufficient scientific and financial interest on the part of the pharmaceutical companies.
 
HNF is particularly grateful to Dr. Jay Tung, a Member of HNF’s Medical Advisory Board and the Vice-President of Drug Discovery at the Myelin Repair Foundation, for his guidance and expertise. HNF is impressed with the Myelin Repair Foundation’s innovative approach to research and their mechanism for driving research forward in the area of Multiple Sclerosis. 
 

Please click on the logo to learn more about the research we fund.